Chlamydia Global Market Report 2025

The chlamydia market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to factors such as the rise in sexual health education programs, increased demand for rapid diagnostic tests, a growing need for cost-effective and scalable STI diagnostics, the expansion of telemedicine, and a heightened focus on precision medicine.

The chlamydia market size is expected to see strong growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth during the forecast period can be attributed to factors such as the rising prevalence of chlamydia, increased public awareness, a growing number of point-of-care testing solutions, the higher prevalence of sexually transmitted diseases, and increasing investments in research and development. Key trends expected in this period include a shift toward point-of-care testing, advancements in molecular diagnostics, a focus on preventative healthcare, the integration of artificial intelligence (AI) in diagnostics, and the development of high-throughput screening platforms.

The growing prevalence of sexually transmitted diseases (STDs) is anticipated to drive the growth of the chlamydia market in the future. STDs are infections transmitted through sexual contact, and include conditions such as chlamydia, gonorrhea, and HIV. The rise in these diseases is linked to factors such as decreased condom use, a lack of awareness, limited healthcare access, and the rise of dating apps, which contribute to having multiple sexual partners. Treatment for chlamydia plays a crucial role in reducing the spread of STDs by curing the infection, preventing complications, and minimizing the risk of transmission to sexual partners. For example, the National Association of County and City Health Officials, a US-based nonprofit organization, reported in June 2024 that in 2022, the U.S. recorded over 2.5 million cases of syphilis, gonorrhea, and chlamydia. Among these, syphilis cases surged by 80%, while congenital syphilis cases saw a dramatic increase of 937%. The number of congenital syphilis cases rose by 31% from 2021 to 2022, totaling 3,755 cases. This surge in sexually transmitted diseases is expected to fuel the growth of the chlamydia market.

The expansion of telemedicine services is also expected to contribute to the growth of the chlamydia market. Telemedicine services involve the use of digital communication tools such as video calls, mobile apps, and remote monitoring to provide healthcare remotely. This growth is driven by advances in digital health technology, wider access to high-speed internet, and the increasing demand for remote healthcare options. Telemedicine supports the chlamydia market by offering patients the convenience of remote consultations, secure prescriptions, and discreet follow-up care, all of which can improve treatment adherence and ensure timely care. For example, FAIR Health Inc., a US-based nonprofit organization, reported a 7.3% increase in telehealth usage across the nation, from 5.5% in December 2022 to 5.9% in January 2023. Additionally, according to Rock Health, a US-based venture capital firm, 80% of survey respondents in 2022 reported using telemedicine at least once, an 8-percentage-point increase from 72% in 2021. The growing availability of telemedicine is expected to drive the growth of the chlamydia market.

Companies in the chlamydia market are also focusing on developing fully automated instruments to improve diagnostic accuracy, reduce human error, and enhance testing efficiency. A fully automated instrument is a system or device that performs tasks autonomously, using sensors, control systems, and artificial intelligence. For example, in May 2022, Becton, Dickinson and Company (BD), a US-based medical device company, launched the BD COR MX/PX System. The BD CTGCTV2 molecular assay, the first test available on this new system, detects the three most common non-viral sexually transmitted infections (STIs), chlamydia trachomatis, neisseria gonorrhoeae, and trichomonas vaginalis. These infections, if left untreated, can lead to serious health issues, such as pregnancy complications and a heightened risk of HIV. The development of such automated instruments will likely improve testing accuracy and efficiency in the chlamydia market.

Major players in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, and Laxai Pharma Ltd.

North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chlamydia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chlamydia is a common sexually transmitted infection (STI) caused by Chlamydia trachomatis. It is often asymptomatic but can lead to complications such as infertility and pelvic inflammatory disease if left untreated. Chlamydia is easily treatable with antibiotics, and prevention involves practicing safe sex and undergoing regular STI screenings.

The main types of tests for chlamydia include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, and others. Culture tests involve growing bacteria from a sample in a laboratory to identify infections such as chlamydia. A healthcare provider collects a sample from the patient - usually from the cervix, urethra, or throat, and places it in a special culture medium. If chlamydia bacteria grow, the infection is confirmed. While reliable, these tests may take longer than other methods. Treatment involves medications administered through various routes, including oral, injectable, and others. These treatments are used by various end users, such as hospitals, diagnostic centers, ambulatory surgical centers, and others.

The chlamydia market research report is one of a series of new reports that provides chlamydia market statistics, including the chlamydia industry global market size, regional shares, competitors with the chlamydia market share, detailed chlamydia market segments, market trends, and opportunities, and any further data you may need to thrive in the chlamydia industry. This chlamydia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia market includes revenues earned by entities by entities by providing services such as diagnostic testing services, screening programs, treatment services, telehealth and online consultations and related products such as lateral flow assays, enzyme-linked immunosorbent assay (Elisa) kits, multiplex STI panels, macrolides, and fluoroquinolones. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.